Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen.
Edward J Gane, Mitchell L Shiffman, Kyle Etzkorn, Giuseppe Morelli, Catherine AM Stedman, Mitchell N Davis, Federico Hinestrosa, Hadas Dvory-Sobol, KC Huang, Anu Osinusi, John McNally, Diana M Brainard, John G McHutchison, Alex J Thompson, Mark S Sulkowski, undefined GS-US-342-1553 Investigators
Hepatology | Published : 2017
The optimal retreatment strategy for patients chronically infected with hepatitis C virus who experience virologic failure after treatment with direct-acting antiviral-based therapies remains unclear. In this multicenter, open-label, phase 2 study, we evaluated the efficacy and safety of a fixed-dose combination of sofosbuvir-velpatasvir (400 mg/100 mg) plus weight-adjusted ribavirin administered for 24 weeks in patients who did not achieve sustained virologic response after prior treatment with direct-acting antiviral regimens that included the nucleotide analogue nonstructural protein 5B inhibitor sofosbuvir plus the nonstructural protein 5A inhibitor velpatasvir with or without the nonstr..View full abstract
Awarded by NIDA NIH HHS